788RO
Start here
At ESMO 2026, three phase II studies examined treatment strategies after targeted therapy in BRAF V600E-mutant metastatic colorectal cancer. The ECLYPse trial met its primary endpoint, TRIDENTE demonstrated clinical activity, and BRICKET, which tested ctDNA-guided retreatment, recorded no objective responses. Together the trials map a mixed picture of options for patients whose disease has progressed on prior targeted therapy in this molecular subtype. Detailed results beyond the headline outcomes have not yet been reported, and questions remain open about which patients are most likely to benefit and how these strategies should be sequenced in practice.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPick2026 ESMO: ECLYPse, TRIDENTE and BRICKET Test Post-Targeted-Therapy Strategies in BRAF V600E-Mutant mCRC, ctDNA-Guided Retreatment Shows No Objective Responses
At ESMO 2026, three phase II studies of post-targeted-therapy strategies in BRAF V600E-mutant metastatic colorectal cancer (mCRC) were presented: ECLYPse met its primary endpoint, TRIDENTE showed clinical activity, and BRICKET observed no objective responses.
Heat trend for this story
Heat now 12·Peak in the comparable set 21 (Oct 25 20:00)·Change over 24h in the comparable set -3%·Participants now 4
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.